2025 has been a year for the history books at Clarius.
We are proud to announce that this year marked a pivotal turning point in our journey to democratize medical imaging. By working more efficiently, while never compromising on the science behind our technology, Clarius has achieved profitability in FY2025 and secured 20% year-over-year revenue growth.
This milestone is about more than just numbers; it validates our mission. It proves that a sustainable, profitable model exists for high-quality, AI-powered handheld ultrasound in a competitive market.
As our CEO, Laurent Pelissier, noted:
2025 has been a pivotal year where our commitment to evidence-based clinical innovation was converged with rigorous operational execution. Achieving profitability while simultaneously launching FDA-cleared AI models demonstrates that Clarius is not just growing, we are securing the future of handheld ultrasound. »
Leading the Charge in AI and Clinical Validation
Artificial Intelligence is no longer just a buzzword—it is a daily tool for our users. This year, we cemented our position as an AI leader in the Point-of-Care Ultrasound (POCUS) space.
We introduced two new FDA-cleared AI models in 2025, bringing our total number of FDA-cleared models to 6, with 16 AI technologies now deployed across education, diagnostic, and workflow applications.
Two of our standout innovations this year include:
Clarius T-Mode™ Shoulder, the newest of seven T-Mode Models that use AI to help clinicians to elevate their scanning skills. Watch this video to see how T-Mode™ Shoulder instantly identifies and differentiates anatomical structures and tissue layers and overlays distinctive colors, patterns, and labels to help with shoulder assessments.
Clarius Prostate AI: Automatically identifies the prostate and performs measurements to calculate volume and PSA Density for urological assessments.
Watch this video to see Clarius Prostate AI in action. It uses artificial intelligence to identify the prostate and perform measurements to calculate prostate volume and PSA Density.
Global Recognition & Expansion
Our efforts to push the boundaries of medical imaging haven’t gone unnoticed. We were honored to be named one of TIME’s « World’s Top HealthTech Companies of 2025, » earning a top ranking in the Medical Devices & Wearables category.
Internationally, our footprint is larger than ever. We have:
- Expanded our distribution network to serve over 70 countries.
- Doubled our growth in the Indo-Pacific region.
- Selected as one of only eight companies for Canada’s Global Hypergrowth Program.
New Frontiers: Pharma & Product Innovation
This year, we expanded our ecosystem beyond direct clinical care. By partnering with leading pharmaceutical companies and Contract Research Organizations (CROs), Clarius scanners are now established as proven tools for evidence-based innovation in drug development and clinical trials.
On the product side, we didn’t slow down. We released over 60 new features across four major software updates, including:
- Expanded T-Mode™ capabilities for breast, shoulder, and abdominal scanning.
- Auto Preset AI tailored for veterinary medicine.
- A robust IP portfolio that now includes 110 patents (with 83 granted), protecting the unique technology that makes our scanners industry-leading.
Empowering the Community
Education remains at the heart of what we do. If you attended a medical tradeshow this year, you likely saw us there—we participated in over 80 global events and hosted 15 clinical webinars. We also grew our education partner network to 29 organizations worldwide, ensuring that as the technology improves, the skills to use it remain accessible.
Looking Ahead to 2026
We’re entering 2026 on solid ground. Our financial strength allows us to aggressively expand our AI capabilities and new partnerships, ensuring that affordable, high-quality ultrasound becomes the standard of care for healthcare providers worldwide.
Thank you to our partners, customers, and team for making 2025 our best year yet.
